Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Transitional Cell × bicalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 118 Breast Neoplasms 10 Neoplasm Metastasis 6 Neoplasms 5 Triple Negative Breast Neoplasms 4 Bulbo-Spinal Atrophy, X-Linked 4 Salivary Gland Neoplasms 2 Prostate Adenocarcinoma 2 Osteoporosis 2 Lower Urinary Tract Symptoms 2 Hirsutism 2 Thrombocytosis 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Primary Myelofibrosis 1 Primary Dysautonomias 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1

Interventions

pembrolizumab 76 Gemcitabine 47 Nivolumab 40 Cisplatin 34 atezolizumab 29 Carboplatin 27 avelumab 22 Docetaxel 22 enfortumab vedotin 21 Magnetic Resonance Spectroscopy 16 Paclitaxel 15 Ipilimumab 15 Specimen Handling 12 Mitomycin 12 durvalumab 10 toripalimab 9 sacituzumab govitecan 9 Pemetrexed 8 vinflunine 7 cabozantinib 7 Taxes 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Standard of Care 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡